CompletedPhase 2NCT00168064
Safety and Efficacy of Nitrogen Mustard in Treatment of Mycosis Fungoides
Studying Aggressive primary cutaneous T-cell lymphoma
Last synced from ClinicalTrials.gov
ℹ
Clinical trial records are synced from ClinicalTrials.gov through automated extraction.
Report missing dataKey facts
- Sponsor
- Yaupon Therapeutics
- Principal Investigator
- Stuart Lessin, M.D., Pharm.DFox Chase Cancer Center
- Intervention
- mechlorethamine-MCH (nitrogen mustard)(drug)
- Enrollment
- 260 enrolled
- Eligibility
- All sexes
- Timeline
- 2006 – 2011
Study locations (12)
- Stanford University Medical Center, Stanford, California, United States
- Northwestern University - Dept. of Dermatology, Chicago, Illinois, United States
- NYU Medical Center Dept. of Dermatology, New York, New York, United States
- Columbia University, Dept. of Dermatology, New York, New York, United States
- Duke University Medical Center, Durham, North Carolina, United States
- Oklahoma University, Tulsa, Oklahoma, United States
- University of Pennsylvania, Philadelphia, Pennsylvania, United States
- Fox Chase Cancer Center, Philadelphia, Pennsylvania, United States
- University of Texas, Southwestern Medical Center, Dallas, Texas, United States
- The University of Texas, M.D. Anderson Cancer Center, Houston, Texas, United States
- Utah Clinical Trials, LLC, Salt Lake City, Utah, United States
- University of Wisconsin, Madison, Wisconsin, United States
Primary source
Recruitment status, site addresses, contacts, and full eligibility criteria can change between syncs. Always verify with the trial team before planning travel or treatment.
Open NCT00168064 on ClinicalTrials.govOther trials for Aggressive primary cutaneous T-cell lymphoma
Additional recruiting or active studies for the same condition.
- RECRUITINGPHASE1NCT05544968Anti-CD30 biAb-AATC in Patients With Relapsed/Refractory CD30 Positive Hematopoietic MalignanciesMedical College of Wisconsin
- RECRUITINGPHASE1NCT07055477A Phase I Trial Anti-CC Chemokine Receptor 4 Chimeric Antigen Receptor T Cells (CCR4 CAR T Cells) for CCR4 Expressing T-cell Malignancies Including Peripheral T-cell Non-Hodgkin Lymphoma (PTCL) and Cutaneous T-cell Non-Hodgkin Lymphoma (CTCL)National Cancer Institute (NCI)
- RECRUITINGPHASE1NCT07047885Ropeginterferon in Patients w/Cutaneous T-Cell Lymphoma (CTCL)H. Lee Moffitt Cancer Center and Research Institute
- RECRUITINGNANCT06860880Combating Cancer-Related Fatigue: A Personalized Supportive Care ProgramUNC Lineberger Comprehensive Cancer Center
- RECRUITINGPHASE1, PHASE2NCT07022964CD5 CAR T-Cell Therapy for r/r T-cell LymphomasBeijing GoBroad Hospital
- RECRUITINGNCT07132567Assessment of Safety and Efficacy of Poteligeo Inj. 20 mg (Mogamulizumab) Through Use-result SurveillanceKyowa Kirin Co., Ltd.
- RECRUITINGPHASE1, PHASE2NCT06925464CD7 CAR T-Cell Therapy for r/r T-cell LymphomasBeijing GoBroad Hospital
- RECRUITINGPHASE1NCT06914037A Clinical Study of CHT101 in CD70-Positive Relapsed or Refractory Hematological MalignanciesTianjin Medical University Cancer Institute and Hospital
See all trials for Aggressive primary cutaneous T-cell lymphoma →